Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| Ankara University | Other Grant/Funding Number | Ankara University Research Fund (10B3330012) |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of the study is to investigate the plasma levels of Soluble Urokinase Plasminogen Activator Receptor (suPAR) at the diagnosis and after treatment of sepsis, and to determine whether it has a diagnostic and prognostic value in late-onset neonatal sepsis.
Infection is a leading cause of neonatal morbidity and mortality worldwide. The clinical presentation of neonatal infection is subtle and nonspecific. Microbiologic cultures of clinical specimens, the gold standard for diagnosis, have low sensitivity and are not available in time to influence initial therapy. Therefore, reliable and rapid in vitro tests are needed for early diagnosis and management of infection in neonates. suPAR, secreted from the cells (neutrophils, lymphocytes, macrophages, endothelial cells) has recently been reported to be a potential biomarker for several infection diseases. The levels of suPAR have not been studied in newborn infants yet.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| septic | Infants having clinical suspected late-onset neonatal sepsis enrolled in the study. Blood samples for suPAR were obtained before initiating antibiotic treatment and at the end of the treatment with other laboratory tests. | ||
| non-septic | Infants without any clinical or hematological septic signs. Blood samples will be taken only once. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Levels of suPAR in late-onset neonatal sepsis | Levels of suPAR will be dosed with suspicion of late-onset sepsis diagnosis at day 0 and at the end of the treatment. The evolution and the best cut-off values will be calculated for the diagnosis. Indices of sensibility, specificity, positive predictive value and negative predictive value will be calculated. | three weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Level of plasma C-reactive protein | Plasma C-reactive protein levels to confirm the diagnostic usefulness of suPAR measurements at diagnosis and end of the treatment | three weeks |
| the white blood cell count |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Infants in Ankara University neonatal intensive care unit
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Saadet Arsan, Professor | Ankara University | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Ankara University Faculty of Medicine, Department of Pediatrics | Ankara | 06620 | Turkey (Türkiye) |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 25043869 | Derived | Okulu E, Arsan S, Akin IM, Ates C, Alan S, Kilic A, Atasay B. Serum Levels of Soluble Urokinase Plasminogen Activator Receptor in Infants with Late-onset Sepsis. J Clin Lab Anal. 2015 Sep;29(5):347-52. doi: 10.1002/jcla.21777. Epub 2014 Jul 10. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000071074 | Neonatal Sepsis |
| D018805 | Sepsis |
| ID | Term |
|---|---|
| D007239 | Infections |
| D007232 | Infant, Newborn, Diseases |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D018746 | Systemic Inflammatory Response Syndrome |
Not provided
Not provided
Not provided
Not provided
Not provided
Serum
the white blood cell counts to confirm the diagnostic usefulness of suPAR measurements at diagnosis and end of the treatment
| three weeks |
| D007249 | Inflammation |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |